1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
EPAM reported first-quarter 2025 revenue of $1.302 billion, up 11.7% from a year earlier, but GAAP diluted EPS fell 35.0% to $1.28 and non-GAAP diluted EPS fell 2.0% to $2.41. The company raised its full-year 2025 revenue growth outlook to 11.5% to 14.5%, and CEO Arkadiy Dobkin will become Executive Chairman on September 1, 2025, with Balazs Fejes succeeding him as CEO and President. Organic constant currency revenue growth was 1.4% in the quarter, so most of the reported growth came from acquisitions and currency effects.
Q1 2025 revenue was $1.302 billion, up 11.7%; organic constant currency growth was 1.4%
Q1 GAAP diluted EPS was $1.28, down 35.0%; non-GAAP diluted EPS was $2.41, down 2.0%
Full-year 2025 revenue growth outlook raised to 11.5% to 14.5%; GAAP diluted EPS outlook is $6.78 to $7.03
Balazs Fejes becomes CEO and President effective September 1, 2025, succeeding Arkadiy Dobkin, who becomes Executive Chairman
Kinetik Holdings reported first quarter 2025 results, with total operating revenues of $443.3 million, up from $341.4 million a year earlier, and Adjusted EBITDA of $250.0 million, up from $233.6 million. Net income fell to $19.3 million from $35.4 million, and diluted earnings per share were $0.05 versus $0.12, while the company affirmed its 2025 Adjusted EBITDA guidance of $1.09 billion to $1.15 billion and raised its share repurchase authorization to $500 million.
Total operating revenues were $443.3 million, compared with $341.4 million in the first quarter of 2024.
Net income including noncontrolling interest was $19.3 million, versus $35.4 million; diluted EPS was $0.05, versus $0.12.
Adjusted EBITDA was $250.0 million, versus $233.6 million; the company said current commodity futures would reduce full-year Adjusted EBITDA by about $20 million.
The Board authorized an increase to the share repurchase program to $500 million and affirmed 2025 Adjusted EBITDA guidance of $1.09 billion to $1.15 billion.
Goodyear reported first quarter 2025 net sales of $4.3 billion, down from $4.5 billion a year earlier, and net income of $115 million (40 cents per share), helped by a $260 million estimated gain on the sale of its Off-the-Road tire business. Excluding significant items, the company posted an adjusted net loss of $11 million (a loss of 4 cents per share), compared with adjusted net income of $29 million a year earlier. On May 7, 2025, it also completed the sale of the Dunlop brand rights to Sumitomo Rubber Industries for $735 million in gross cash proceeds, which Goodyear says it intends to use to reduce leverage.
Q1 2025 net sales were $4.3 billion, compared with $4.5 billion in Q1 2024; GAAP net income was $115 million (40 cents per share) versus a net loss of $57 million (20 cents per share) a year earlier.
Adjusted net loss was $11 million (a loss of $0.04 per share), compared with adjusted net income of $29 million ($0.10 per share) in the prior year quarter.
Segment operating income was $195 million, down $52 million from a year ago, driven by higher raw material costs, with Goodyear Forward benefits of $200 million.
The Dunlop brand sale to Sumitomo Rubber Industries closed May 7, 2025, with gross cash proceeds of $735 million, including $526 million for the brand.
Tetra Tech reported second-quarter fiscal 2025 revenue of $1.322 billion, up 6% year over year, and adjusted EPS of $0.33, up 18%, and raised its full-year net revenue and adjusted EPS guidance. GAAP EPS fell to $0.02 from $0.28 after a $92.4 million non-cash goodwill impairment tied to terminated USAID contracts. The company also entered a $1.5 billion credit agreement maturing in 2030 and declared a $0.065 quarterly dividend, up 12%.
Q2 revenue $1.322 billion (up 6%); net revenue $1.104 billion (up 5%); reported operating income $39.6 million vs. $117.7 million a year earlier
FY25 net revenue guidance raised to $4.400 billion to $4.765 billion; adjusted EPS guidance raised to $1.42 to $1.52
Credit agreement dated May 5, 2025: $250 million 5-year term loan, $600 million revolver, $250 million 3-year term loan; matures 2030 (5-year) and May 5, 2028 (3-year)
Quarterly dividend of $0.065 per share payable June 5, 2025 to holders of record May 23, 2025; additional $500 million buyback approved, leaving $673 million available
Corteva reported first-quarter 2025 results, with net sales down 2% to $4.42 billion while GAAP earnings per share from continuing operations rose to $0.97 from $0.53. The company reaffirmed its full-year 2025 guidance, including net sales of $17.2 to $17.6 billion and operating EPS of $2.70 to $2.95, which matters to shareholders because profit grew faster than sales while the outlook was left unchanged.
Net sales were $4.42 billion, down 2% from $4.49 billion a year earlier; organic sales rose 3%.
GAAP EPS from continuing operations was $0.97 versus $0.53; operating EPS was $1.13, up 27%.
Full-year 2025 guidance reaffirmed: net sales $17.2 to $17.6 billion, operating EBITDA $3.6 to $3.8 billion, operating EPS $2.70 to $2.95.
The company plans to repurchase approximately $1 billion of shares during 2025.
Watts Water Technologies reported first quarter 2025 sales of $558 million, down 2% from a year earlier, while diluted earnings per share rose 2% to $2.21. The company kept its full year 2025 organic sales and adjusted operating margin outlook and raised its quarterly dividend 21% to $0.52 per share, which matters to shareholders because it signals higher cash returns despite the lower sales.
Net sales were $558.0 million, down 2% from $570.9 million, with fewer shipping days and European destocking cited as drivers
GAAP operating income fell 9% to $87.7 million and operating margin declined 120 basis points to 15.7%; adjusted operating margin rose 80 basis points to 19.0%
Diluted EPS was $2.21 versus $2.17; adjusted diluted EPS was $2.37 versus $2.33
Quarterly dividend increases from $0.43 to $0.52 per share beginning June 2025; full year outlook maintained
Axon reported first-quarter 2025 revenue of $604 million, up 31% year over year, and raised its full-year 2025 revenue outlook to $2.60 billion to $2.70 billion. The company also said on May 1, 2025, its Audit Committee concluded that its 2024 annual financial statements and the 2024 quarterly statements for March 31 and September 30 should no longer be relied upon, because $690.0 million of convertible notes were presented as long-term rather than current liabilities. Total assets, total liabilities and stockholders' equity were not affected, but the filing discloses an additional material weakness in internal control over financial reporting.
Q1 2025 revenue of $604 million, up 31% year over year; net income of $88 million, or $1.08 per diluted share
Full-year 2025 revenue outlook raised to $2.60 billion to $2.70 billion, from $2.55 billion to $2.65 billion
Audit Committee concluded on May 1, 2025 that 2024 annual and 2024 Q1 and Q3 financial statements should no longer be relied upon
The $690.0 million 2027 convertible notes are reclassified from long-term to current liabilities; an additional material weakness in internal controls was identified
Concentra reported first-quarter 2025 revenue up 7.1% to $500.8 million and raised its full-year 2025 revenue and Adjusted EBITDA guidance. Net income fell 19.2% to $40.6 million, and earnings per share were $0.30 versus $0.47, which the company attributed to higher interest expense from its IPO recapitalization. The Board also declared a $0.0625 per share cash dividend.
Q1 2025 revenue was $500.8 million, up from $467.6 million; net income was $40.6 million, down from $50.3 million
Earnings per share were $0.30 versus $0.47 a year earlier; adjusted EPS was $0.32 versus $0.49
2025 guidance now calls for revenue of $2.1 billion to $2.15 billion and Adjusted EBITDA of $415 million to $430 million
Dividend of $0.0625 per share is payable May 29, 2025, to holders of record on May 20, 2025; the $55 million Pivot Onsite Innovations acquisition is expected to close in Q2 2025
MKS Instruments reported first quarter 2025 revenue of $936 million, at the high end of its guidance and up from $868 million a year earlier, with GAAP net income of $52 million ($0.77 per diluted share) versus $15 million ($0.22) in the first quarter of 2024. For the second quarter, the company guided to revenue of $925 million, plus or minus $40 million, and Non-GAAP net earnings per diluted share of $1.56, plus or minus $0.28, both below first-quarter actual results.
Q1 2025 total net revenues of $936 million, versus $935 million in Q4 2024 and $868 million in Q1 2024
Q1 2025 GAAP net income of $52 million and diluted EPS of $0.77; Non-GAAP net earnings of $116 million and $1.71 per diluted share
Q2 2025 guidance: revenue of $925 million plus or minus $40 million; GAAP net income per diluted share of $0.81 plus or minus $0.32
Free cash flow of $123 million in Q1 2025; company repurchased about 546,000 shares for about $45 million and paid a $15 million dividend
Marriott Vacations Worldwide reported first-quarter 2025 results, with revenues excluding cost reimbursements up 3% to $827 million and GAAP diluted EPS up 20% to $1.46. Adjusted diluted EPS fell 8% to $1.66 and consolidated contract sales declined 2% to $420 million, while the company reiterated its full-year 2025 Adjusted EBITDA outlook of $750 million to $780 million. The company also said it will post a new investor presentation on its website on May 8, 2025.
Revenues excluding cost reimbursements rose 3% to $827 million; net income attributable to common stockholders was $56 million, up from $47 million.
Adjusted diluted EPS was $1.66 versus $1.80 a year earlier, down 8%; Adjusted EBITDA rose 3% to $192 million.
Consolidated contract sales fell 2% to $420 million; Exchange & Third-Party Management segment Adjusted EBITDA fell 13% to $28 million.
2025 guidance includes Adjusted EBITDA of $750 million to $780 million (reiterated) and Adjusted EPS - diluted of $6.40 to $7.10; a conference call is set for May 8, 2025 at 8:30 a.m. ET.
Sonos reported second-quarter fiscal 2025 results for the period ended March 29, 2025, with revenue of $259.8 million, up from $252.7 million a year earlier. The GAAP net loss was $70.1 million, or $0.58 per diluted share, compared with a loss of $69.7 million, or $0.56 per share, a year earlier. The company did not give guidance in the release and said it will provide it on the earnings call.
Revenue of $259.8 million vs. $252.7 million in the second quarter of fiscal 2024
GAAP net loss of $70.1 million, or $0.58 per diluted share; non-GAAP net loss of $21.7 million, or $0.18 per share
Adjusted EBITDA loss of $0.8 million vs. a loss of $33.6 million a year earlier
No guidance in the release; company will provide guidance on the May 7, 2025 earnings call
Helmerich & Payne reported fiscal second-quarter 2025 results for the quarter ended March 31, 2025, after completing its KCA Deutag acquisition on January 16, 2025. Operating revenues rose to $1.0 billion from $687.9 million a year earlier, but net income attributable to the company fell to $1.7 million, or $0.01 per diluted share, from $84.8 million, or $0.84 per diluted share. The company also expects third-quarter direct margin in each segment to be lower than the strong North America Solutions result, and it now targets $50 to $75 million in overall cost reductions.
Operating revenues were $1,016.0 million, compared with $687.9 million a year earlier and $677.3 million in the prior quarter.
Net income attributable to Helmerich & Payne was $1.7 million ($0.01 per diluted share), versus $84.8 million ($0.84 per diluted share) a year earlier; transaction and integration costs were $29.9 million.
Management expects overall cost structure reductions of $50 to $75 million, with the full impact recognized in fiscal 2026.
Third-quarter guidance includes North America Solutions direct margin of $235 million to $260 million and International Solutions direct margin of $25 million to $35 million.
Fidelity National Financial reported first-quarter 2025 GAAP net earnings attributable to common shareholders of $83 million, or $0.30 per diluted share, down from $248 million, or $0.91, a year earlier. Adjusted net earnings rose to $213 million, or $0.78 per share, from $206 million, or $0.76, while total revenue fell to $2.7 billion from $3.3 billion.
GAAP net earnings were $83 million ($0.30 per diluted share) versus $248 million ($0.91) in Q1 2024; the company says the GAAP figure includes mark-to-market effects and non-recurring items.
Adjusted net earnings were $213 million ($0.78 per share) versus $206 million ($0.76) in Q1 2024.
Title segment adjusted pre-tax margin was 11.7% versus 10.7%; F&G Segment had a net loss of $18 million for the quarter, driven by unfavorable mark-to-market movement.
FNF repurchased 390,000 shares for $25 million in late Q1 and paid $136 million in common dividends, or $0.50 per share.
Crane NXT reported first quarter 2025 sales of $330.3 million, up 5.3% from a year earlier, but GAAP earnings per diluted share fell to $0.38 from $0.66 as operating profit dropped to $37.3 million from $55.4 million. The company raised its full year 2025 sales growth guidance to 6% to 8% and kept its adjusted EPS guidance at $4.00 to $4.30, after completing the De La Rue Authentication acquisition on May 1, 2025.
Q1 2025 sales were $330.3 million, up 5.3%, with acquisitions adding $33.4 million and core sales down 4.1%.
GAAP EPS was $0.38 versus $0.66 a year earlier; adjusted EPS was $0.54 versus $0.85.
Full year 2025 sales growth guidance was raised to 6% to 8% from 1% to 3%; adjusted EPS guidance of $4.00 to $4.30 was unchanged.
The company completed the De La Rue Authentication acquisition on May 1, 2025 for £300 million in cash and declared a $0.17 quarterly dividend payable June 11, 2025.
Jackson Financial reported a first-quarter 2025 net loss attributable to common shareholders of $35 million, or $0.48 per diluted share, compared with net income of $784 million, or $9.94 per diluted share, a year earlier. The company attributed the loss partly to a $161 million loss from business reinsured to third parties, and said adjusted operating earnings, a non-GAAP measure, better reflect underlying performance. Adjusted operating earnings rose to $376 million, or $5.10 per diluted share, from $334 million, or $4.23 per diluted share, helped by higher spread income and fewer diluted shares.
GAAP net loss of $35 million, or $0.48 per diluted share, versus net income of $784 million, or $9.94 per diluted share, in Q1 2024
Adjusted operating earnings of $376 million, or $5.10 per diluted share, versus $334 million, or $4.23 per diluted share, in Q1 2024
Retail annuity sales of $4.0 billion, up 9% from the first quarter of 2024
Returned $231 million to common shareholders in Q1 2025: $172 million in share repurchases and $59 million in dividends
Innoviva reported first-quarter 2025 total revenue of $88.6 million, up from $77.5 million a year earlier, and income from operations rose 61% to $41.4 million. Unfavorable fair value changes in equity and long-term investments of $78.8 million produced a net loss of $46.6 million, or $0.74 per basic share, compared with net income of $36.5 million, or $0.58 per share, in the first quarter of 2024. The results are mixed for shareholders: operating performance improved, but investment valuation losses turned the bottom line negative.
Total revenue was $88.6 million versus $77.5 million; income from operations was $41.4 million, up from $25.8 million.
U.S. net product sales were $26.4 million, a 52% increase year over year, led by $17.4 million from GIAPREZA.
Net loss was $46.6 million, or $0.74 per basic share, versus net income of $36.5 million, or $0.58 per share.
Gross royalty revenue from GSK was $61.3 million, compared with $61.9 million; cash and cash equivalents were $319.1 million at March 31, 2025.
NCR Atleos reported first quarter 2025 results, with revenue down 7% year over year to $980 million from $1.05 billion. Profit measures improved: GAAP net income was $17 million compared with a net loss of $8 million a year earlier, and non-GAAP diluted EPS rose 56% to $0.64. The company reaffirmed its full year 2025 guidance ranges, so shareholders get a mixed picture of weaker sales alongside higher profit.
Revenue was $980 million, down from $1.05 billion in the prior-year quarter, with recurring revenue at 76% of the total
GAAP diluted EPS was $0.23 versus $(0.11) a year earlier; non-GAAP diluted EPS was $0.64 versus $0.41
Adjusted EBITDA grew 9% to $175 million, and the company reaffirmed its full year 2025 guidance ranges
Conference call to discuss the results is scheduled for May 8, 2025 at 8:30 a.m. Eastern Time
Paycom reported first-quarter 2025 revenue of $530.5 million, up 6.1% from a year earlier, and non-GAAP net income of $157.7 million, or $2.80 per diluted share. GAAP net income fell to $139.4 million, or $2.48 per diluted share, from $247.2 million a year earlier, when results included a $117.5 million benefit from a forfeited CEO performance award. Chief executive Chad Richison said the company is raising its outlook for 2025.
Q1 2025 total revenues were $530.5 million, up 6.1% from $499.9 million.
GAAP net income was $139.4 million, or $2.48 per diluted share, versus $247.2 million, or $4.37, in Q1 2024, which included a $117.5 million benefit.
Non-GAAP net income was $157.7 million, or $2.80 per diluted share, versus $146.6 million, or $2.59, a year earlier.
2025 guidance: total revenue of $2.023 billion to $2.038 billion and adjusted EBITDA of $843.0 million to $858.0 million.
Digi International reported fiscal second-quarter 2025 results for the period ended March 31, 2025. Revenue fell 3% to $105 million, while net income rose to $10 million from $4 million and diluted EPS rose to $0.28 from $0.11. The company raised its fiscal 2025 profit outlook, now projecting Adjusted EBITDA growth of 5%, but its revenue outlook of roughly flat year over year is unchanged.
Revenue was $105 million, down 3% year over year; ARR reached $123 million, up 12%.
Net income was $10 million ($0.28 per diluted share) versus $4 million ($0.11) a year earlier; adjusted EPS was $0.51 versus $0.49.
Fiscal 2025 Adjusted EBITDA is now projected to grow 5% year over year, up from a prior projection of roughly flat.
Debt was reduced to $70.0 million at quarter end; the company expects a net cash positive position at fiscal year end.
Genpact reported first-quarter 2025 net revenues of $1.215 billion, up 7.4% year-over-year, and adjusted diluted EPS of $0.84, up 16%. The company cut its full-year 2025 revenue growth outlook to 2.0% to 5.0% from 5.5% to 7.5%, and lowered its adjusted diluted EPS range to $3.41 to $3.52 from $3.52 to $3.59, which matters to shareholders because the earnings forecast came down even as quarterly results grew.
Q1 2025 net income was $131 million, up 12%, and diluted EPS was $0.73, up 14%.
Full-year 2025 net revenue guidance is $4.862 billion to $5.005 billion, down from the prior growth range of 5.5% to 7.5%.
Full-year 2025 adjusted diluted EPS guidance is $3.41 to $3.52, down from $3.52 to $3.59.
Genpact repurchased about 1.2 million shares for approximately $63 million during the quarter.
QuidelOrtho reported first-quarter 2025 revenue of $693 million, down from $711 million a year earlier, mainly due to lower COVID-19 and Donor Screening sales. Adjusted diluted EPS rose to $0.74 from $0.44, and GAAP net loss narrowed to $13 million from $1.71 billion, which included a prior-year goodwill impairment charge. The company maintained its full-year 2025 guidance, so shareholders see weaker sales offset by higher profitability.
Total revenue was $693 million versus $711 million a year earlier; non-respiratory revenue was flat at $573 million.
Adjusted diluted EPS was $0.74, compared with $0.44 in the prior-year period; adjusted EBITDA was $160 million versus $132 million.
GAAP net loss was $13 million, compared with $1.71 billion a year earlier, which included a $1.74 billion goodwill impairment charge.
Full-year 2025 guidance was maintained, including reported revenue of $2.60 to $2.81 billion and adjusted diluted EPS of $2.07 to $2.57.
Schrödinger reported first-quarter 2025 total revenue of $59.6 million, up 63% from $36.6 million a year earlier, led by software revenue of $48.8 million. The net loss widened to $59.8 million from $54.7 million, and the loss per share was $0.82 compared with $0.76. The company maintained its previously issued 2025 financial guidance.
Total revenue rose 63% to $59.6 million; software revenue rose 46% to $48.8 million, partly due to early renewals by large customers.
Net loss was $59.8 million versus $54.7 million a year earlier; loss per share was $0.82 versus $0.76.
Non-GAAP net loss was $46.7 million versus $62.4 million in the first quarter of 2024.
Full-year 2025 guidance was maintained, including software revenue growth of 10% to 15% and drug discovery revenue of $45 million to $50 million.
CoreCivic reported first-quarter 2025 net income of $25.1 million, or $0.23 per diluted share, up from $9.5 million, or $0.08, a year earlier, while revenue fell to $488.6 million from $500.7 million. The prior-year quarter included $27.2 million of debt refinancing expenses, and on an adjusted basis diluted EPS was $0.25 a year earlier, so adjusted EPS declined. The company raised its full-year 2025 net income guidance to $91.3 million to $101.3 million, reflecting reactivation of idle facilities under ICE agreements.
Q1 2025 revenue was $488.6 million, versus $500.7 million in Q1 2024; ICE revenue was $133.2 million, versus $153.8 million.
Q1 2025 net income was $25.1 million ($0.23 diluted EPS), versus $9.5 million ($0.08) in Q1 2024; Q1 2024 adjusted diluted EPS was $0.25.
Full-year 2025 net income guidance was raised to $91.3 million to $101.3 million from $53.5 million to $67.5 million; diluted EPS guidance rose to $0.83 to $0.92 from $0.48 to $0.61.
In Q1 2025 the company repurchased 1.9 million shares for $37.9 million, leaving $131.0 million of authorization as of March 31, 2025.
Century Aluminum reported first quarter 2025 results on May 7, 2025. Net sales rose $3.0 million from the fourth quarter to $633.9 million, but net income attributable to Century stockholders fell $15.5 million to $29.7 million, and diluted EPS dropped to $0.29 from $0.44, mainly due to higher input costs and derivative losses. The company expects second quarter Adjusted EBITDA of $80 million to $90 million.
Net sales of $633.9 million, up $3.0 million sequentially; net income attributable to Century stockholders of $29.7 million, down from $45.2 million
Diluted EPS of $0.29 versus $0.44 in the fourth quarter of 2024; adjusted EPS of $0.36 versus $0.42
Adjusted EBITDA attributable to Century stockholders of $78.0 million, down $2.9 million sequentially
Q2 2025 outlook: Adjusted EBITDA of $80 million to $90 million; liquidity of $339.1 million at March 31, 2025
Central Garden & Pet reported fiscal second-quarter 2025 results for the period ended March 29, 2025. Net sales fell 7% to $834 million, while GAAP diluted EPS rose to $0.98 from $0.93, and the company reaffirmed its fiscal 2025 non-GAAP EPS outlook of $2.20 or better, which matters to shareholders because sales declined even as per-share earnings grew.
Net sales were $834 million, down 7%; Pet segment sales fell 6% to $454 million and Garden segment sales fell 10% to $380 million.
GAAP diluted EPS was $0.98 versus $0.93 a year earlier; non-GAAP diluted EPS was $1.04 versus $0.99.
Fiscal 2025 non-GAAP EPS outlook was reaffirmed at $2.20 or better.
Central repurchased $41 million of stock during the quarter and $39 million more through April 30, 2025, with $63 million remaining available.
Coherent Corp. reported fiscal third-quarter 2025 results for the quarter ended March 31, 2025, with revenue of $1.50 billion, up 24% from a year earlier. GAAP results remained a loss of $0.11 per diluted share, though that was an improvement from a loss of $0.29 a year earlier, and the quarter included $73.8 million in restructuring charges. The company also issued fourth-quarter fiscal 2025 guidance, which shareholders can compare with these results.
Q3 revenue was $1.50 billion, up 23.9% year over year, with networking revenue of $897.3 million.
GAAP diluted loss per share was $(0.11), compared with $(0.29) in the year-ago quarter; non-GAAP diluted EPS was $0.91, compared with $0.38.
Restructuring charges were $73.8 million in the quarter, compared with $8.0 million in the prior quarter.
Fourth-quarter fiscal 2025 guidance calls for revenue of $1.425 billion to $1.575 billion and non-GAAP EPS of $0.81 to $1.01.
RB Global reported first-quarter 2025 results, with total revenue up 4% year over year to $1.1 billion and diluted EPS up 4% to $0.55, while gross transaction value fell 6% and adjusted EPS and adjusted EBITDA each declined 1%. The company left its full-year 2025 outlook unchanged and declared a quarterly dividend of $0.29 per share, payable June 20, 2025.
Total revenue rose 4% to $1.1 billion; net income available to common stockholders rose 6% to $102.9 million.
Diluted adjusted EPS fell 1% to $0.89 and adjusted EBITDA fell 1% to $327.9 million.
GTV decreased 6% to $3.8 billion, mainly due to a decline in the commercial construction and transportation sector.
2025 outlook is unchanged, including adjusted EBITDA of $1,320 million to $1,380 million; quarterly dividend of $0.29 per share declared May 6, 2025.
Alpha and Omega Semiconductor (AOS) reported fiscal third-quarter 2025 results for the quarter ended March 31, 2025. Revenue rose 9.7% from a year earlier to $164.6 million but fell 4.9% from the prior quarter, and the GAAP net loss was $10.8 million, or $0.37 per diluted share, compared with a $0.23 loss per share in the prior quarter. The company guided fiscal fourth-quarter revenue to approximately $170 million, plus or minus $10 million, compared with the $164.6 million reported for the quarter just ended.
Revenue was $164.6 million, down 4.9% from the December 2024 quarter and up 9.7% from the March 2024 quarter.
GAAP net loss was $10.8 million, or $0.37 per diluted share, versus a $0.23 loss per share in the prior quarter and a $0.39 loss per share a year earlier.
Non-GAAP net loss was $2.9 million, or $0.10 per share, compared with non-GAAP net income of $0.09 per share in the prior quarter.
Fiscal fourth-quarter 2025 revenue outlook is approximately $170 million, plus or minus $10 million; GAAP gross margin is expected at 22.9%, plus or minus 1%.
BorgWarner reported first-quarter 2025 net sales of $3,515 million, down about 2% from a year earlier, and GAAP earnings of $0.72 per diluted share, down from $0.93. Adjusted earnings rose about 8% to $1.11 per share after excluding non-comparable items, mainly impairment charges and restructuring costs. The company also said it will exit its Charging business and narrowed its full-year adjusted EPS range to $4.00 to $4.45 from $4.05 to $4.40.
Q1 2025 GAAP operating income was $237 million (6.7% of net sales), down from $295 million in Q1 2024; adjusted operating margin was 10.0%.
Adjusted EPS of $1.11 compares with $1.03 a year earlier; non-comparable items reduced GAAP EPS by $0.39 per share.
Full-year 2025 net sales guidance is $13.6 billion to $14.2 billion, a slight increase, while the weighted light and commercial vehicle market outlook was cut to down 4% to down 2%.
The company will exit its Charging business in Q2 2025, which it expects to eliminate about $30 million of annualized adjusted operating losses.
Lantheus reported first-quarter 2025 revenue of $372.8 million, up 0.8% from a year earlier, while GAAP diluted earnings per share fell to $1.02 from $1.87 and adjusted diluted EPS fell 9.5% to $1.53. The company lowered its full-year 2025 adjusted diluted EPS guidance to $6.60-$6.70 from $7.00-$7.20, which means lower expected profit for shareholders even as revenue guidance was narrowed.
Q1 2025 GAAP diluted EPS was $1.02, down from $1.87; adjusted diluted EPS was $1.53, down 9.5% from $1.69.
FY2025 adjusted diluted EPS guidance cut to $6.60-$6.70, from $7.00-$7.20 issued February 26, 2025.
FY2025 revenue guidance narrowed to $1.550-$1.585 billion, from $1.545-$1.610 billion.
Agreed to sell the SPECT business to SHINE; the transaction is expected to close by the end of 2025.
Payoneer reported first-quarter 2025 revenue of $246.6 million, up 8% from a year earlier, while net income fell 29% to $20.6 million. The company suspended its previously issued full-year 2025 guidance, citing macroeconomic uncertainty, so shareholders no longer have a company forecast for the year.
Revenue was $246.6 million, up 8% year over year; revenue excluding interest income was $188.6 million, up 16%.
Net income was $20.6 million versus $29.0 million a year earlier; diluted EPS was $0.05 versus $0.08.
Adjusted EBITDA was $65.4 million, flat year over year, and interest income fell 11% to $58.0 million.
Full-year 2025 guidance was suspended, with the company citing the current macroeconomic uncertainty.
Jones Lang LaSalle reported first-quarter 2025 revenue of $5.7 billion, up 13% in local currency, and adjusted diluted EPS of $2.31, up 28%. GAAP diluted EPS fell 17% to $1.14, which the company attributes to non-cash losses, and operating cash flow was negative $767.6 million.
Revenue was $5,746.4 million, up 12% in dollars and 13% in local currency, the fourth consecutive quarter of double-digit growth.
Diluted EPS was $1.14, down 17% from $1.37; adjusted diluted EPS was $2.31, up 30% in dollars from $1.78.
Equity losses were $25.6 million, compared with $3.7 million a year earlier; net income attributable to common shareholders was $55.3 million versus $66.1 million.
Cash flows from operating activities were negative $767.6 million, and $993.4 million remained authorized for share repurchases as of March 31, 2025.
HNI Corporation reported first quarter 2025 results for the period ended March 29, 2025, with net sales up 2.0% to $599.8 million and net income of $13.9 million. GAAP diluted EPS fell to $0.29 from $0.37, weighed down by $6.4 million in restructuring and impairment charges tied mainly to HNI India, while non-GAAP diluted EPS rose to $0.44 from $0.37. The company said its 2025 earnings outlook is unchanged, with double-digit percent EPS growth still expected, which matters to shareholders because management is holding its full-year profit view despite tariff pressures.
Net sales were $599.8 million, up 2.0% from $588.0 million in the first quarter of 2024.
GAAP diluted EPS was $0.29 versus $0.37 a year earlier; non-GAAP diluted EPS was $0.44 versus $0.37.
Restructuring and impairment charges totaled $6.4 million, primarily an impairment tied to the HNI India business classified as held for sale.
The 2025 earnings outlook is unchanged, and the company repurchased $40 million of its stock in the quarter.
Charles River Laboratories reported first-quarter 2025 revenue of $984.2 million, down 2.7% from $1,011.6 million a year earlier, with GAAP diluted earnings per share of $0.50 versus $1.30. Non-GAAP diluted EPS rose 3.1% to $2.34, and the company raised its 2025 non-GAAP EPS guidance to $9.30 to $9.80 from $9.10 to $9.60, which matters to shareholders because revenue and GAAP profit declined while the outlook moved higher.
Q1 2025 revenue was $984.2 million, down 2.7% from $1,011.6 million; organic revenue fell 1.8%.
GAAP diluted EPS was $0.50 versus $1.30 in Q1 2024; non-GAAP diluted EPS was $2.34 versus $2.27.
2025 non-GAAP EPS guidance raised to $9.30 to $9.80 from $9.10 to $9.60; reported revenue guidance is now (5.5)% to (3.5)%.
The company repurchased $350 million of common stock in Q1 and had $549.3 million remaining on its $1.0 billion authorization as of March 29, 2025.
Diebold Nixdorf reported first-quarter 2025 revenue of $841.1 million, down 6.1% from $895.4 million a year earlier, and adjusted EBITDA of $87.3 million, down from $103.3 million. The company still posted a smaller net loss of $7.5 million, versus $14.0 million a year earlier, and free cash flow was $6.1 million compared with a use of $36.4 million. The company kept its full-year 2025 outlook, including adjusted EBITDA of $470 million to $490 million, and cited uncertainty from U.S. tariff policy.
Revenue was $841.1 million, down 6.1% year over year; GAAP gross margin rose 80 basis points to 24.1%.
Net loss attributable to Diebold Nixdorf was $8.3 million, or $(0.22) per share, versus $14.6 million, or $(0.39) per share, a year earlier.
Order entry rose 36% year over year, and product backlog increased to approximately $900 million.
2025 guidance was maintained: adjusted EBITDA $470 million to $490 million, free cash flow $190 million to $210 million, and total revenue flat to up low single digits.
Trimble reported first-quarter 2025 revenue of $840.6 million, down 12% from a year earlier but up 2% on an organic basis, and GAAP diluted EPS of $0.27 versus $0.23, while non-GAAP diluted EPS fell to $0.61 from $0.64. The company kept its full-year 2025 guidance, which reflects the February 8, 2025 closing of the mobility divestiture, and spent $627.4 million on share repurchases in the quarter.
Revenue $840.6 million, down 12% year over year from $953.3 million; up 2% organic
Middleby reported first-quarter 2025 net sales of $906.6 million, down 2.2% from a year earlier, while GAAP diluted EPS rose to $1.69 from $1.59 and adjusted EBITDA fell to $182.1 million from $185.8 million. The board also raised the share repurchase authorization by 7.5 million shares, leaving 11.4 million shares available, which the company says equals 21% of its outstanding equity, and it is targeting most free cash flow for buybacks.
Net sales were $906.6 million, down 2.2% from $926.9 million; organic net sales fell 3.8%.
Net earnings rose to $92.4 million from $86.6 million; diluted EPS was $1.69 versus $1.59.
Adjusted EBITDA was $182.1 million versus $185.8 million a year earlier.
On May 5, 2025, the board added 7.5 million shares to the buyback, bringing shares available to 11.4 million; about $50 million was repurchased year to date.
Rockwell Automation reported fiscal second-quarter 2025 sales of $2,001 million, down 6% from $2,126 million a year earlier, and diluted EPS of $2.22, down from $2.31. The company raised its fiscal 2025 diluted EPS guidance to $8.23 to $9.23 from $7.65 to $8.85, while its reported sales growth guidance range moved to (4.5)% to 1.5% from (5.5)% to 0.5%.
Q2 fiscal 2025 reported sales were $2,001 million, down 6%; organic sales fell 4% and currency reduced sales by 2%.
Diluted EPS was $2.22 versus $2.31 a year earlier; adjusted EPS was $2.45 versus $2.50.
Fiscal 2025 diluted EPS guidance rose to $8.23 to $9.23 and adjusted EPS guidance to $9.20 to $10.20, versus prior ranges of $7.65 to $8.85 and $8.60 to $9.80.
The company repurchased about 0.5 million shares for $129 million in the quarter, with about $1.1 billion remaining under authorizations.
Steven Madden completed its acquisition of Kurt Geiger on May 6, 2025, and entered into a new credit agreement with a $300 million term loan and a $250 million revolving credit facility, secured by the company's and subsidiaries' assets. In first-quarter results, revenue rose 0.2% to $553.5 million, but net income attributable to the company fell to $40.4 million from $43.9 million and diluted EPS fell to $0.57 from $0.60. The company also withdrew its 2025 guidance because of tariff uncertainty, so shareholders now have higher debt and no current outlook, while the $0.21 quarterly dividend was maintained.
Kurt Geiger acquisition closed May 6, 2025, at an enterprise value of approximately £289 million, funded by borrowings under the new credit agreement and cash on hand
New credit agreement provides a $300 million term loan and $250 million revolving credit facility, maturing May 6, 2030
Q1 2025 revenue rose 0.2% to $553.5 million; diluted EPS was $0.57 versus $0.60 a year earlier
2025 financial guidance withdrawn due to tariff uncertainty; quarterly dividend of $0.21 per share payable June 20, 2025
Performance Food Group reported fiscal third-quarter 2025 results for the quarter ended March 29, 2025. Net sales rose 10.5% to $15.3 billion and Adjusted EBITDA rose 20.1% to $385.1 million, but net income fell 17.2% to $58.3 million and diluted EPS fell 17.8% to $0.37; the company also lowered the top end of its full-year net sales and Adjusted EBITDA ranges, citing a difficult February, which matters to shareholders because the company's outlook for fiscal 2025 is now lower at the high end.
Net sales for the quarter rose 10.5% to $15.3 billion, while net income fell 17.2% to $58.3 million and diluted EPS fell 17.8% to $0.37.
Full-year fiscal 2025 net sales outlook is now $63 billion to $63.5 billion, down from $63 billion to $64 billion.
Full-year fiscal 2025 Adjusted EBITDA outlook is now $1.725 billion to $1.75 billion, down from $1.725 billion to $1.8 billion.
Operating cash flow for the first nine months was $827.1 million, compared with $956.7 million a year earlier.
Bruker reported first quarter 2025 revenue of $801.4 million, up 11.0% year over year, but non-GAAP diluted EPS fell 11.3% to $0.47 and GAAP diluted EPS was $0.11, down from $0.35. The company lowered its full-year 2025 organic revenue growth and non-GAAP EPS guidance, citing academic market and tariff dynamics, which points to a weaker profit outlook for shareholders.
Adient reported a net loss attributable to Adient of $335 million, or $3.99 per diluted share, for the quarter ended March 31, 2025, compared with a loss of $70 million, or $0.77 per share, a year earlier. Net sales fell to $3.61 billion from $3.75 billion, and restructuring and impairment costs rose to $351 million, including a $333 million goodwill impairment. Adjusted diluted earnings per share rose to $0.69 from $0.54, so shareholders face a larger reported loss alongside higher adjusted profit.
Net sales were $3.61 billion, down from $3.75 billion a year earlier.
Net loss attributable to Adient was $335 million, or $3.99 per diluted share, versus $70 million, or $0.77 per share.
Adjusted diluted earnings per share were $0.69, up from $0.54; adjusted EBITDA was $233 million, up from $227 million.
Cash used by operating activities was $45 million, and net debt was $1.64 billion at March 31, 2025.
Emerson reported fiscal second-quarter results for the quarter ended March 31, 2025, with net sales up 1% to $4.43 billion and adjusted EPS up 9% to $1.48. GAAP EPS fell 9% to $0.86, and pretax earnings declined to $629 million from $711 million, reflecting transaction-related costs tied to the AspenTech buy-in. The company raised its fiscal 2025 net sales growth guidance to about 4% and its adjusted EPS guidance at the midpoint, while lowering the GAAP EPS outlook to $4.05 to $4.20.
Net sales rose to $4,432 million from $4,376 million; underlying sales grew 2% and underlying orders grew 4%.
Adjusted EPS was $1.48 versus $1.36, while GAAP EPS was $0.86 versus $0.95, with acquisition and divestiture fees of $168 million in the quarter.
Fiscal 2025 adjusted EPS guidance is $5.90 to $6.05; operating cash flow guidance is $3.5 billion to $3.6 billion and free cash flow guidance is $3.1 billion to $3.2 billion.
The 2025 outlook assumes about $2.3 billion returned to shareholders, including $1.1 billion of share repurchases; the company completed the AspenTech buy-in on March 12, 2025.
Kennametal reported fiscal 2025 third-quarter results for the period ended March 31, 2025. Sales fell 6% to $486 million, while adjusted EPS rose to $0.47 from $0.30, helped by an approximately $10 million advanced manufacturing production credit under the Inflation Reduction Act. The company updated its full-year outlook, now expecting sales of $1.970 billion to $1.990 billion and adjusted EPS of $1.30 to $1.45.
Diluted EPS was $0.41 versus $0.24, and adjusted EPS was $0.47 versus $0.30, in the prior year quarter.
Sales of $486 million decreased 6% from $516 million, with an organic sales decline of 3%.
The quarter includes an approximately $10 million Inflation Reduction Act production credit within the Infrastructure segment.
Full-year fiscal 2025 outlook: sales of $1.970 billion to $1.990 billion and adjusted EPS of $1.30 to $1.45; quarterly dividend of $0.20 per share payable May 27, 2025.
RXO reported first-quarter 2025 revenue of $1.4 billion, up from $913 million a year earlier, and adjusted EBITDA of $22 million, up from $15 million. GAAP net loss widened to $31 million from $15 million, including $20 million of transaction, integration, restructuring and other costs. The company also said Coyote coverage operations have moved onto its RXO Connect platform and raised its cash synergy estimate to more than $70 million.
Revenue was $1.433 billion versus $913 million in Q1 2024; gross margin was 16.0% versus 17.4%.
GAAP diluted loss per share was $0.18 versus $0.13; adjusted diluted loss per share was $0.03 in both periods.
Second-quarter 2025 outlook: adjusted EBITDA of $30 million to $40 million and Brokerage gross margin of 13% to 15%.
Cash synergy estimate raised to greater than $70 million, excluding cost-of-purchased-transportation opportunities.
Elanco reported first-quarter 2025 revenue of $1,193 million, down 1% from a year earlier, while adjusted EPS rose 9% to $0.37. The company raised its full-year 2025 revenue guidance to $4,510 million to $4,580 million, but its reported net loss guidance widened to $(35) million to $(7) million, and adjusted EBITDA fell 6% in the quarter.
Q1 2025 revenue was $1,193 million, down 1% reported and up 4% organic constant currency
Adjusted EBITDA was $276 million, down 6%; reported net income rose to $67 million from $32 million
Full-year 2025 revenue guidance raised to $4,510 million to $4,580 million; adjusted EBITDA ($830 million to $870 million) and adjusted EPS ($0.80 to $0.86) maintained
Reported net loss guidance is now $(35) million to $(7) million, versus $(25) million to $7 million in February
Bio-Techne reported fiscal third-quarter results for the period ended March 31, 2025, with net sales up 4% to $316.2 million and adjusted EPS up to $0.56 from $0.48. GAAP EPS fell to $0.14 from $0.31, as GAAP operating income dropped 42% to $38.7 million, which the company tied to a non-recurring arbitration award and $38.9 million in certain litigation charges. The company also declared an $0.08 quarterly dividend and approved a new $500 million share repurchase program.
Net sales were $316.2 million, up 4% reported and 6% organic.
GAAP EPS was $0.14 versus $0.31 a year earlier; adjusted EPS was $0.56 versus $0.48.
GAAP operating income fell 42% to $38.7 million, including $38.9 million in certain litigation charges.
Dividend of $0.08 per share payable May 30, 2025; new $500 million buyback begins May 8, 2025.
LivaNova reported first-quarter 2025 revenue of $316.9 million, up 7.4% from a year earlier, and raised its full-year revenue growth guidance. The company also recorded a $360.4 million SNIA environmental liability after an Italian Supreme Court ruling, producing a U.S. GAAP diluted loss of $6.01 per share, and lowered its full-year adjusted diluted EPS guidance to $3.60 to $3.70 from $3.65 to $3.75.
Q1 2025 revenue $316.9 million, up 7.4% reported and 10.4% organic; Cardiopulmonary revenue rose 13.1%
GAAP diluted loss of $6.01 per share versus $0.78 loss a year earlier, driven by the SNIA environmental liability; adjusted diluted EPS $0.88 versus $0.73
Full-year 2025 revenue growth guidance raised to 6.0% to 7.0% constant-currency; adjusted diluted EPS guidance lowered to $3.60 to $3.70, incorporating an estimated $0.20 SNIA impact
Adjusted free cash flow guidance unchanged at $135 million to $155 million
Axalta reported first quarter 2025 net sales of $1.26 billion, down 3% year over year, while net income rose 154% to $99 million. The profit gain was largely due to $55 million of prior-year expenses tied to its 2024 Transformation Initiative, and adjusted diluted EPS rose 16% to $0.59. The company also issued second quarter and full year 2025 outlook ranges, including full year adjusted EBITDA of $1,150 million to $1,175 million.
Net sales were $1.26 billion, down 3%, with a 3% foreign currency headwind; volume declines were primarily in Performance Coatings.
Diluted EPS rose to $0.45 from $0.18; adjusted diluted EPS rose 16% to $0.59.
Adjusted EBITDA was a first quarter record of $270 million, up 4%, with a margin of 21.4%.
Free cash flow was negative $14 million, compared with $15 million in the prior year period; operating cash flow was $26 million.
Owens Corning reported first-quarter 2025 results on May 7, 2025. Net sales from continuing operations rose 25% to $2.5 billion, but diluted EPS from continuing operations fell 7% to $2.95 and the company posted a net loss of $93 million after a $348 million loss from discontinued operations. For the second quarter, the company expects revenue from continuing operations to grow at a high-single-digit percent and adjusted EBITDA margin in the low-to-mid 20 percent range.
Net sales from continuing operations were $2.5 billion ($2,530 million), up 25%, with the newly acquired Doors business contributing $540 million.
Diluted EPS from continuing operations was $2.95 versus $3.16 a year earlier; adjusted diluted EPS was $2.97 versus $3.40.
Net loss was $93 million, including a $348 million net loss from discontinued operations, which now includes the glass reinforcements business.
Second-quarter 2025 outlook calls for high-single-digit revenue growth; the company will hold its 2025 Investor Day on May 14, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.